Pentosan polysulfate
| Clinical data | |
|---|---|
| Trade names | Elmiron, Zycosan |
| Other names | PPS, (1->4)-β-Xylan 2,3-bis(hydrogen sulfate) with a 4 O-methyl-α-D-glucuronate |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth, intramuscular |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Excretion | Feces, urine |
| Identifiers | |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H18O21S4 |
| Molar mass | 602.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pentosan polysulfate, sold under the brand name Elmiron among others, is a medication used for interstitial cystitis. Evidence of benefit; however, is mixed as of 2024. It is recommended that the medication be stopped if there is no improvement within 6 months. It was approved for medical use in the United States in 1996.